Clinical Trials | December 29, 2025
Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The primary goal of the collaboration is joint research into trending and next-generation molecules
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Subscribe To Our Newsletter & Stay Updated
